WO2011139106A3 - 혈장 내 pgcp 농도 측정을 통한 치매 진단 방법 - Google Patents

혈장 내 pgcp 농도 측정을 통한 치매 진단 방법 Download PDF

Info

Publication number
WO2011139106A3
WO2011139106A3 PCT/KR2011/003361 KR2011003361W WO2011139106A3 WO 2011139106 A3 WO2011139106 A3 WO 2011139106A3 KR 2011003361 W KR2011003361 W KR 2011003361W WO 2011139106 A3 WO2011139106 A3 WO 2011139106A3
Authority
WO
WIPO (PCT)
Prior art keywords
dementia
pgcp
diagnosis
plasma
measuring concentration
Prior art date
Application number
PCT/KR2011/003361
Other languages
English (en)
French (fr)
Other versions
WO2011139106A2 (ko
Inventor
안상미
장봉금
안경숙
Original Assignee
대한민국(관리부서 질병관리본부장)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대한민국(관리부서 질병관리본부장) filed Critical 대한민국(관리부서 질병관리본부장)
Publication of WO2011139106A2 publication Critical patent/WO2011139106A2/ko
Publication of WO2011139106A3 publication Critical patent/WO2011139106A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

본 발명은 혈장 내 존재하는 PGCP의 농도 측정을 통한 치매 진단 방법에 관한 것으로, 보다 상세하게는 치매 환자의 혈장 내 PGCP가 정상인군 및 경도인지장애군에 비해 현저히 높은 농도로 존재함을 확인함으로써, 상기 PGCP 단백질을 진단 마커로 이용하여 치매 진단 키트를 구성하고, 이를 이용하여 치매 진단 방법에 유용하게 사용할 수 있다.
PCT/KR2011/003361 2010-05-06 2011-05-04 혈장 내 pgcp 농도 측정을 통한 치매 진단 방법 WO2011139106A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100042335A KR101250464B1 (ko) 2010-05-06 2010-05-06 혈장 내 ｐｇｃｐ 농도 측정을 통한 치매 진단 방법
KR10-2010-0042335 2010-05-06

Publications (2)

Publication Number Publication Date
WO2011139106A2 WO2011139106A2 (ko) 2011-11-10
WO2011139106A3 true WO2011139106A3 (ko) 2012-04-19

Family

ID=44904237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/003361 WO2011139106A2 (ko) 2010-05-06 2011-05-04 혈장 내 pgcp 농도 측정을 통한 치매 진단 방법

Country Status (2)

Country Link
KR (1) KR101250464B1 (ko)
WO (1) WO2011139106A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210003568A1 (en) * 2019-07-04 2021-01-07 Adtech Co., Ltd. Novel pregnancy diagnosis device including beta-core fragment hcg as marker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100499989B1 (ko) * 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
KR100595494B1 (ko) * 2003-02-24 2006-07-03 (주) 디지탈바이오텍 혈액 내 베타-아밀로이드 항체 농도를 이용한 알츠하이머병 진단키트
WO2005076003A2 (en) * 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
KR20090009579A (ko) * 2007-07-20 2009-01-23 영인프런티어(주) 알츠하이머병 진단용 마커 및 이를 이용한 진단키트

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PEDER BUCHHAVE ET AL.: "Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease", NEUROSCI. LETT., vol. 450, no. 1, 2009, pages 56 - 59, XP025800600, DOI: doi:10.1016/j.neulet.2008.10.091 *
RICHARD GINGRAS ET AL.: "Purification, cDNA Cloning, and Expression of a New Human Blood Plasma Glutamate Carboxypeptidase Homologous to N-Acetyl-aspartyl-a-glutamate Carboxypeptidase/Prostate-specific Membrane Antigen", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 17, 1999, pages 11742 - 11750, XP002337889, DOI: doi:10.1074/jbc.274.17.11742 *
TAE-SUK KIM ET AL.: "Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease", NEUROSCI. LETT., vol. 436, no. 2, 2008, pages 196 - 200, XP022613113, DOI: doi:10.1016/j.neulet.2008.03.019 *

Also Published As

Publication number Publication date
KR20110122958A (ko) 2011-11-14
WO2011139106A2 (ko) 2011-11-10
KR101250464B1 (ko) 2013-04-15

Similar Documents

Publication Publication Date Title
PH12014501108A1 (en) Anti-il-36r antibodies
HK1206065A1 (en) Compositions and methods for analyte detection
EP2609220A4 (en) ASSOCIATION OF RARE RECURRENT GENETIC VARIATIONS WITH HYPERACTIVITY (ADHD) ATTENTION DEFICIT DISORDER AND ASSOCIATED METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF ADHD
AP2014007533A0 (en) Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
IL222252A (en) A system, device and method for detecting and diagnosing biological arrhythmias
ZA201208543B (en) High concentration antibody formulations
EP2487486B8 (en) PH Sensor, PH measurement method, ION sensor and ION concentration measurement method
WO2012129341A3 (en) Disease detection in plants
EP2600761A4 (en) MEMBRANE COMPOSITION FOR BIOSENSOR, BIOSENSOR AND METHODS OF MAKING THE SAME
EP2761016A4 (en) REDOX REAGENT COMPOSITION FOR ELECTROCHEMICAL BIOSENSOR AND BIOSENSOR CONTAINING THE SAME
EP2563409A4 (en) SYSTEM AND METHOD FOR MEASURING X-RAY PHARMACEUTICAL CONCENTRATION
EP2757371A4 (en) METHOD FOR ANALYZING THE SENSITIVITY TO AN ANTIBACTERIAL MEDICINE OF A BACTERIUM OR A FUNGUS, AND A SYSTEM USED FOR ITS IMPLEMENTATION
HK1176646A1 (en) Methods for the detection of biologically relevant molecules and their interaction characteristics
EP2686688A4 (en) SYSTEMS AND COMPOSITIONS FOR DIAGNOSIS OF BARRETT OSOPHAGES AND METHOD OF USE THEREOF
IN2015DN00924A (ko)
EP2726876A4 (en) METHOD FOR DETERMINING AN ACTIVE CONCENTRATION THROUGH CALIBRATION-FREE ANALYSIS
WO2014001229A3 (en) Cell penetrating peptides & methods of identifying cell penetrating peptides
PL2650358T3 (pl) Mikroorganizm o ulepszonej zdolności wytwarzania ornityny i sposób wytwarzania ornityny z jego użyciem
HK1186484A1 (zh) 同等型富集的抗體製備物及其獲得方法
IN2015KN00073A (ko)
WO2012129299A3 (en) Medical instruments and methods for fabricating same
GB201105045D0 (en) Optical assembly and method for determining analyte concentration
WO2011119986A3 (en) Methods for culturing and analyzing cells
EP2539354A4 (en) FOR RANTES-CODING NUCLEIC ACID MOLECULES AND COMPOSITIONS AND METHODS THEREWITH

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11777587

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11777587

Country of ref document: EP

Kind code of ref document: A2